Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ernexa Therapeutics (ERNA) FCF Margin (2016 - 2024)

Historic FCF Margin for Ernexa Therapeutics (ERNA) over the last 14 years, with Q4 2024 value amounting to 18657.89%.

  • Ernexa Therapeutics' FCF Margin fell 91068700.0% to 18657.89% in Q4 2024 from the same period last year, while for Sep 2025 it was 49710.53%, marking a year-over-year decrease of 469581500.0%. This contributed to the annual value of 2700.83% for FY2024, which is 177261700.0% up from last year.
  • According to the latest figures from Q4 2024, Ernexa Therapeutics' FCF Margin is 18657.89%, which was down 91068700.0% from 1294.46% recorded in Q3 2024.
  • Over the past 5 years, Ernexa Therapeutics' FCF Margin peaked at 29857.14% during Q2 2022, and registered a low of 18657.89% during Q4 2024.
  • Moreover, its 4-year median value for FCF Margin was 793.46% (2024), whereas its average is 1979.58%.
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by -283446400bps in 2023, then soared by 101290700bps in 2024.
  • Quarter analysis of 4 years shows Ernexa Therapeutics' FCF Margin stood at 140.47% in 2020, then surged by 21355bps to 29857.14% in 2022, then tumbled by -132bps to 9551.02% in 2023, then tumbled by -95bps to 18657.89% in 2024.
  • Its last three reported values are 18657.89% in Q4 2024, 1294.46% for Q3 2024, and 5336.17% during Q2 2024.